表1：有关2型糖尿病的一般建议.....................................................................................................................................................................................................................................................................................................HTA Analysis for SFDA-Registered New Molecules ...........................................................9 Table 3: Guidelines Requiring Revision ....................................................................................................... 11 Table 4.ADA Grading/Level of Evidence .................................................................................................... 11 Table 6.Revised Logical Ranking of Scientific Methodologies (Step I: Evidence Rating) ............................................................................................................................................................................. 18 Table 7: List of the Additional Guidelines ................................................................................................. 22 Table 8.Australian Diabetes Society Grading/Level of Evidence .............................................. 23 Table 9.加拿大糖尿病等级/证据水平........................................................................................................................................................................................................... 24表10。Drug Therapy with Ertugliflozin ................................................................................................ 29 Table 11.Ertugliflozin HTA Analysis ............................................................................................................... 33 Table 12.Drug Therapy with Tirzepatide................................................................................................... 35 Table 13.Tirzepatide HTA Analysis ............................................................................................................... 40 Table 14.Drug Therapy with Semaglutide ............................................................................................... 41 Table 15.semaglutide HTA分析........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 46表16。degludec-liraglutide的药物治疗..................................................................................................................................................................................................................................................................................................................... 48表17。Degludec-Liraglutide HTA Analysis ......................................................................................... 53 Table 18.Drug Therapy with Glargine-Lixisenatide ........................................................................... 55 Table 19.甘醇 - 脂肪烯二烯HTA分析........................................................................................................................................................................................................................................... 60